Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078598604> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2078598604 endingPage "510" @default.
- W2078598604 startingPage "505" @default.
- W2078598604 abstract "Purpose A phase II study evaluated weekly docetaxel/gemcitabine as first-line chemotherapy for locally recurrent or metastatic breast cancer in a multicenter community oncology practice setting. Patients and Methods Eligible patients who had not received chemotherapy for metastatic disease received docetaxel 30 mg/m2 followed by gemcitabine 800 mg/m2, each administered weekly for 3 weeks (days 1, 8, and 15), followed by a 1-week rest period (28-day cycle). Patients also received oral dexamethasone to reduce the incidence/severity of fluid retention and hypersensitivity reactions. Of the 46 enrolled patients, 45 were treated as part of the intent-to-treat (ITT) population and were evaluable for safety. Results There were 3 complete responses and 12 partial responses among the 39 evaluable patients, for an objective response rate (ORR) of 39% (95% confidence interval [CI], 24%–54%). The ORR in the ITT population was 33% (95% CI, 18%–48%). Median time to response was 3.4 months, with a median response duration of 6.7 months. Median survival was 15.8 months, and median time to progression was 5.8 months. The most common grade 3/4 hematologic toxicity was neutropenia (13.3%); there was a low incidence of other grade 3/4 hematologic toxicities. Grade 3 fatigue (15.6%) was the most common grade 3/4 nonhematologic toxicity, and grade 2 alopecia occurred in 47% of patients. One patient who had been receiving chronic corticosteroid therapy died from treatment-related neutropenia and acute respiratory distress syndrome. Conclusion These phase II results suggest that weekly docetaxel/gemcitabine is moderately active and well tolerated as first-line therapy for locally recurrent or metastatic breast cancer. No clear advantage for combined weekly docetaxel/gemcitabine was observed compared with published results on the efficacy of docetaxel and gemcitabine given as single agents." @default.
- W2078598604 created "2016-06-24" @default.
- W2078598604 creator A5012042649 @default.
- W2078598604 creator A5028916394 @default.
- W2078598604 creator A5053161145 @default.
- W2078598604 creator A5058598881 @default.
- W2078598604 creator A5065675425 @default.
- W2078598604 creator A5071432873 @default.
- W2078598604 date "2006-02-01" @default.
- W2078598604 modified "2023-10-17" @default.
- W2078598604 title "Phase II Trial of Weekly Docetaxel/Gemcitabine as First-Line Chemotherapy in Patients with Locally Recurrent or Metastatic Breast Cancer" @default.
- W2078598604 cites W1760955494 @default.
- W2078598604 cites W1812067939 @default.
- W2078598604 cites W1841504999 @default.
- W2078598604 cites W1907604566 @default.
- W2078598604 cites W1920828316 @default.
- W2078598604 cites W1939916640 @default.
- W2078598604 cites W1990656227 @default.
- W2078598604 cites W2013246214 @default.
- W2078598604 cites W2014134856 @default.
- W2078598604 cites W2022915103 @default.
- W2078598604 cites W2052942483 @default.
- W2078598604 cites W2121247384 @default.
- W2078598604 cites W2126942676 @default.
- W2078598604 cites W2141056749 @default.
- W2078598604 cites W2149051430 @default.
- W2078598604 cites W2150067367 @default.
- W2078598604 cites W2228069427 @default.
- W2078598604 doi "https://doi.org/10.3816/cbc.2006.n.003" @default.
- W2078598604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16595033" @default.
- W2078598604 hasPublicationYear "2006" @default.
- W2078598604 type Work @default.
- W2078598604 sameAs 2078598604 @default.
- W2078598604 citedByCount "19" @default.
- W2078598604 countsByYear W20785986042012 @default.
- W2078598604 countsByYear W20785986042014 @default.
- W2078598604 countsByYear W20785986042016 @default.
- W2078598604 crossrefType "journal-article" @default.
- W2078598604 hasAuthorship W2078598604A5012042649 @default.
- W2078598604 hasAuthorship W2078598604A5028916394 @default.
- W2078598604 hasAuthorship W2078598604A5053161145 @default.
- W2078598604 hasAuthorship W2078598604A5058598881 @default.
- W2078598604 hasAuthorship W2078598604A5065675425 @default.
- W2078598604 hasAuthorship W2078598604A5071432873 @default.
- W2078598604 hasConcept C121608353 @default.
- W2078598604 hasConcept C126322002 @default.
- W2078598604 hasConcept C141071460 @default.
- W2078598604 hasConcept C143998085 @default.
- W2078598604 hasConcept C2775930923 @default.
- W2078598604 hasConcept C2776694085 @default.
- W2078598604 hasConcept C2777063308 @default.
- W2078598604 hasConcept C2778850193 @default.
- W2078598604 hasConcept C2780258809 @default.
- W2078598604 hasConcept C2781190966 @default.
- W2078598604 hasConcept C2908647359 @default.
- W2078598604 hasConcept C530470458 @default.
- W2078598604 hasConcept C71924100 @default.
- W2078598604 hasConcept C90924648 @default.
- W2078598604 hasConcept C99454951 @default.
- W2078598604 hasConceptScore W2078598604C121608353 @default.
- W2078598604 hasConceptScore W2078598604C126322002 @default.
- W2078598604 hasConceptScore W2078598604C141071460 @default.
- W2078598604 hasConceptScore W2078598604C143998085 @default.
- W2078598604 hasConceptScore W2078598604C2775930923 @default.
- W2078598604 hasConceptScore W2078598604C2776694085 @default.
- W2078598604 hasConceptScore W2078598604C2777063308 @default.
- W2078598604 hasConceptScore W2078598604C2778850193 @default.
- W2078598604 hasConceptScore W2078598604C2780258809 @default.
- W2078598604 hasConceptScore W2078598604C2781190966 @default.
- W2078598604 hasConceptScore W2078598604C2908647359 @default.
- W2078598604 hasConceptScore W2078598604C530470458 @default.
- W2078598604 hasConceptScore W2078598604C71924100 @default.
- W2078598604 hasConceptScore W2078598604C90924648 @default.
- W2078598604 hasConceptScore W2078598604C99454951 @default.
- W2078598604 hasIssue "6" @default.
- W2078598604 hasLocation W20785986041 @default.
- W2078598604 hasLocation W20785986042 @default.
- W2078598604 hasOpenAccess W2078598604 @default.
- W2078598604 hasPrimaryLocation W20785986041 @default.
- W2078598604 hasRelatedWork W1917321041 @default.
- W2078598604 hasRelatedWork W1965395418 @default.
- W2078598604 hasRelatedWork W1971162671 @default.
- W2078598604 hasRelatedWork W2000475715 @default.
- W2078598604 hasRelatedWork W2004163315 @default.
- W2078598604 hasRelatedWork W2110838388 @default.
- W2078598604 hasRelatedWork W2151941897 @default.
- W2078598604 hasRelatedWork W2347099117 @default.
- W2078598604 hasRelatedWork W2409044894 @default.
- W2078598604 hasRelatedWork W2560259057 @default.
- W2078598604 hasVolume "6" @default.
- W2078598604 isParatext "false" @default.
- W2078598604 isRetracted "false" @default.
- W2078598604 magId "2078598604" @default.
- W2078598604 workType "article" @default.